Determination of the Aneurysm Vulnerability Index by Stimulation and Medical Imaging

NCT ID: NCT05189041

Last Updated: 2022-01-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-06-30

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Stroke is the leading cause of disability in France with 130,000 cases per year, 20% of strokes being hemorrhagic, with a majority of intracranial aneurysm rupture (80%). Each year, 6000 meningeal hemorrhages (MHA) caused by cerebral aneurysm rupture are reported in France: 40% of patients die within the first month and 30% are left with severe and permanent disability. Intracranial aneurysms are present in 2 to 6% of the population and only about 0.5% of them will rupture. Given the human and economic costs associated with this disease, systematic medical screening for intracranial aneurysms could be useful. However, the operative risk of endovascular treatment remains non-zero (around 1%) and could be proposed only to a selected population of aneurysms at risk of rupture. The absence of diagnostic criteria for aneurysmal vulnerability does not allow for the moment to consider screening for this disease, which continues to strike without warning a young and active population.

Nevertheless, access to brain imaging allows the detection of an increasing number of intracranial aneurysms. The question of preventive treatment then arises and is still a difficult point discussed by neurosurgeons / neurointerventionists based on general epidemiological data difficult to apply to an individual.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aneurysm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ruptured Cerebral Aneurysm

Quantify the aneurysmal pulsation in functional MRI on the patient with Ruptured Cerebral Aneurysm

Group Type OTHER

Aneurysmal pulsation in functional MRI

Intervention Type OTHER

Quantify the aneurysmal pulsation in functional MRI on the patient with Ruptured Cerebral Aneurysm

Non Ruptured Cerebral Aneurysm

Quantify the aneurysmal pulsation in functional MRI on the patient with Non Ruptured Cerebral Aneurysm

Group Type OTHER

Aneurysmal pulsation in functional MRI

Intervention Type OTHER

Quantify the aneurysmal pulsation in functional MRI on the patient with Ruptured Cerebral Aneurysm

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Aneurysmal pulsation in functional MRI

Quantify the aneurysmal pulsation in functional MRI on the patient with Ruptured Cerebral Aneurysm

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age limits to \> 18 years
* Collection of the informed consent (patient or legal representant)
* Affiliation or recipient with the mode of social security

\- Groupe anévrysme rompu
* Patient porteur d'un anévrysme rompu

\- Groupe anévrysme non rompu
* Patient porteur d'un anévrysme non rompu

Exclusion Criteria

* Subject presenting contraindications in MRI (Ferromagnetic foreign bodies, pace-maker …)
* Claustrophobia
* Women pregnant or Breast-feeding
* Patient participating in an other study
* Patient have participated in a study in the 3 months before the inclusion
* In period of exclusion relative to another protocol
* Person with majority age protected by the law (supervision or trusteeship).
* Patient not reading the french language
* Patient or representant for whom it impossible to give accurate informations
Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Montpellier

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

VINCENT COSTALAT

Role: STUDY_DIRECTOR

University Hospital, Montpellier

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

COSTALAT

Montpellier, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

9364

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.